Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

20 May 2020

2398.20

-0.34%

Earnings growth led by US/Asia and better operating leverage

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

20 May 2020 Ajanta Pharma (AJP) ended FY20 on a healthy note with 15% earnings growth (v/s 12% compounded earnings decline over FY17-19), led by sales revival in Asia, Africa and new introductions in the US market. The companys major capex program would conclude in FY21 and only maintenance capex would be required FY22E onwards, indicating better free cash flow situation for AJP. We reduce our EPS estimate for FY21 by 6% to factor in the COVID-19 led slowdown in the branded generics segment. INR6.3b) grew 32% YoY, led by exports (+43%YoY; 74% of sales). Within exports, US generic sales were up 88% YoY (INR1.4b) and emerging markets sales grew 38% YoY (INR3b). Domestic formulation sales grew 11% YoY to INR1.8b (~26% of sales). Gross Margin (GM) came in at 74% and contracted 550bp YoY due to change in the product mix. AJP had forex loss of INR150m in other expenses. Adjusting for the same, EBITDA margin at 24.

Ajanta Pharma Ltd. has lost -25.09% in the last 1 Year

Ajanta Pharma Ltd.

20 Apr 2020

2398.20

-0.34%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

27 Feb 2020

2398.20

-0.34%

Earnings back on track after bottoming out in FY19

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

With stability in industry cash cycle, AJP has enhanced its business scope in the branded markets of Asia and Africa. For branded generics business (67% of sales), AJP has guided for 9- 11% YoY growth for the next three years. Covered market growth in Dermatology for the past five years was 16%, while AJP grew at 8% due to a high base of Melacare range of products and higher attrition in MRs. Going forward, covered market growth is expected to be 9- 10%. Compared to its subdued growth in the past, AJP expects to do better (11- 12%) as (a) MR team being stabilized for this segment, (b) renewed interest in Melacare range of products and (c) new launches lined up in this segment. Considering covered market growth expectation at 7-8%, AJP intends to do better than industry at 10-11% in Cardiology.

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

06 Feb 2020

2398.20

-0.34%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

07 Nov 2019

2398.20

-0.34%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Prabhudas Lilladhar released a Buy report for Ajanta Pharma Ltd. with a price target of 3200.0 on 19 Sep, 2025.

Ajanta Pharma Ltd.

06 Nov 2019

2398.20

-0.34%

Ajanta Pharma - 2QFY20 Result Update

Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

06 Aug 2019

2398.20

-0.34%

Ajanta Pharma Ltd. - Result Update - 06 August 2019

Results Update: Ajanta Pharma Ltd.

Way2Wealth

Ajanta reported growth across most of the financial line items YoY and QoQ. Revenue/EBITDA/PAT grew by 20%/7%/9%YoY, while sequentially it grew by 19%/32%/30%. However, gross and EBITDA margins declined 700bps and 335bps YoY....

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

01 Aug 2019, 12:00AM

2398.20

-0.34%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations - Focus on new launches, few therapies Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Prabhudas Lilladhar released a Buy report for Ajanta Pharma Ltd. with a price target of 3200.0 on 19 Sep, 2025.

Ajanta Pharma Ltd.

01 Aug 2019, 12:00AM

2398.20

-0.34%

Ajanta Pharma - 1QFY20 Result Update

Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

02 May 2019

2398.20

-0.34%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in the dermatology segment due to increased competition in existing products and slow offtake in new launches may impact near term...

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Is Ajanta Pharma Ltd. worth buying?

190 Votes:

Buy 77.37%

Sell 15.79%

Hold 6.84%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf